Drug Price Trends for SIMPONI

Average Pharmacy Cost for SIMPONI

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
SIMPONI 100 MG/ML PEN INJECTOR	57894-0071-02	7446.21259	ML	2026-01-02
SIMPONI 50 MG/0.5 ML SYRINGE	57894-0070-01	12977.24400	ML	2026-01-02
SIMPONI 50 MG/0.5 ML PEN INJEC	57894-0070-02	12974.51782	ML	2026-01-02
SIMPONI 50 MG/0.5 ML SYRINGE	57894-0070-01	12359.28000	ML	2025-12-17
SIMPONI 50 MG/0.5 ML PEN INJEC	57894-0070-02	12356.68364	ML	2025-12-17

SIMPONI (golimumab): Patent Expirations and Market Trajectory Analysis

Last updated: February 19, 2026

This report analyzes the patent landscape and projects the market trajectory for SIMPONI (golimumab), an injectable biologic used to treat autoimmune diseases. Key patents protecting SIMPONI are expiring in the coming years, opening the door for biosimilar competition. This analysis focuses on the patent expiration dates, expected biosimilar entry, and potential price erosion.

What is SIMPONI and its Therapeutic Applications?

SIMPONI is a human monoclonal antibody that selectively inhibits tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine. By blocking TNF-alpha, SIMPONI reduces inflammation and its associated symptoms in patients with autoimmune conditions.

SIMPONI is approved for the treatment of:

• Rheumatoid Arthritis (RA): Moderate to severe active RA in adults who have had an inadequate response or intolerance to methotrexate.
• Psoriatic Arthritis (PsA): Active PsA in adults to relieve the signs and symptoms of PsA.
• Ulcerative Colitis (UC): Moderate to severe active UC in adults who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic.
• Ankylosing Spondylitis (AS): Moderate to severe active AS in adults.

The drug is administered via subcutaneous injection in a pre-filled syringe or autoinjector. The typical dosage regimens vary by indication, with monthly dosing being common for RA, PsA, and AS, and weekly dosing for UC in some cases [1].

What is the Patent Landscape for SIMPONI?

The patent protection for SIMPONI is multifaceted, covering the active pharmaceutical ingredient (API), its formulations, and methods of use. The primary patents of concern for market exclusivity are those protecting the golimumab molecule itself and its manufacturing processes.

The key patent families and their estimated expiration timelines are as follows:

• Core Golimumab Patents: These patents cover the composition of matter for golimumab. The primary patents in this category are U.S. Patent Nos. 7,129,336 and 7,816,094.
  • U.S. Patent No. 7,129,336 is set to expire in September 2027.
  • U.S. Patent No. 7,816,094 is set to expire in August 2026.
• Formulation Patents: Additional patents cover specific formulations of SIMPONI, which may extend protection for particular delivery methods or compositions. For example, U.S. Patent No. 8,030,477 related to a liquid formulation has an expiration in August 2024. While this date precedes the core API patents, it is important to note that generic manufacturers must navigate all relevant patents to avoid infringement.
• Method of Use Patents: Patents covering specific indications or treatment regimens can also influence market exclusivity. However, these are generally less impactful than API composition patents for biosimilar development, as biosimilars aim to replicate the API and are then approved for specific indications.

It is crucial to note that patent challenges, litigation, and potential extensions (such as Hatch-Waxman Act extensions for regulatory delays) can alter these expiration dates. However, based on current publicly available information, the core patents are nearing expiration in 2026 and 2027.

When is Biosimilar Competition Expected for SIMPONI?

The expiration of SIMPONI's core patents will enable the development and submission of biosimilar applications. The pathway for biosimilar approval in the United States is governed by the Biologics Price Competition and Innovation Act (BPCIA). Biosimilar manufacturers must demonstrate a high degree of similarity to the reference product (SIMPONI) in terms of physicochemical properties, biological activity, and clinical safety and efficacy, with no clinically meaningful differences.

Based on typical development timelines for biologics and the current patent landscape, the first biosimilar entries for SIMPONI are anticipated to emerge shortly after the expiration of the key composition of matter patents.

• 2026-2027: This period marks the earliest potential for biosimilar market entry as primary composition of matter patents expire.
• 2028 onwards: Further biosimilar entrants are likely to emerge in the years following the initial approvals, leading to increased competition.

Companies that have demonstrated expertise in biosimilar development, such as Samsung Bioepis, Celltrion, and Sandoz, are likely candidates to pursue SIMPONI biosimilars. The pace of biosimilar development is often influenced by the complexity of the molecule and the manufacturing process. Golimumab, as a monoclonal antibody, presents significant development challenges.

What are the Projected Market Impacts of Biosimilar Entry?

The entry of biosimilars for SIMPONI is expected to significantly impact its market dynamics, primarily through price reduction and increased patient access.

Price Erosion

The introduction of biosimilars to a reference biologic typically leads to substantial price erosion. This erosion is driven by several factors:

• Competition: Multiple biosimilar products competing for market share will naturally drive down prices.
• Reimbursement Policies: Payers and pharmacy benefit managers (PBMs) often incentivize the use of lower-cost biosimilars through formulary placement and rebates.
• Cost of Production: Biosimilar manufacturers often benefit from optimized manufacturing processes and economies of scale, allowing for lower production costs.

Based on trends observed with other TNF-alpha inhibitor biosimilars (e.g., adalimumab, infliximab), SIMPONI could experience price reductions ranging from 20% to 50% or more within the first few years of biosimilar market entry.

• Year 1 Post-Entry: Initial price reduction of 15-25%.
• Years 2-3 Post-Entry: Further price erosion, potentially reaching 25-45% as more competitors enter and uptake increases.
• Years 5+ Post-Entry: Price reductions may stabilize or continue to decline, reaching 40-60% or higher depending on the number of biosimilars approved and market dynamics.

Market Share Shifts

The availability of biosimilars will fragment the market for golimumab. While SIMPONI will likely retain some market share due to established physician and patient familiarity, biosimilars will capture a significant portion of new prescriptions and potentially convert existing patients.

• Early Adoption: Physicians may initially prescribe SIMPONI to established patients, while opting for biosimilars for new patients.
• Payer Influence: Mandated switching policies by payers could accelerate the shift to biosimilars.
• Physician Confidence: As biosimilars gain regulatory approval and demonstrate comparable efficacy and safety, physician confidence will grow, leading to broader adoption.

The market share for SIMPONI is projected to decline gradually, with biosimilars capturing an increasing share of the total golimumab market. Within five years of the first biosimilar launch, SIMPONI's market share could decrease by 30-50%.

Revenue Projections

The revenue for SIMPONI is expected to decline following biosimilar entry. The magnitude of this decline will be directly correlated with the degree of price erosion and market share loss.

• Pre-Biosimilar Era: SIMPONI's revenue has shown consistent growth, driven by increasing diagnoses of autoimmune diseases and its efficacy profile. For instance, Janssen's (a division of Johnson & Johnson) reported sales for SIMPONI and SIMPONI ARIA (intravenous formulation) were approximately $2.6 billion in 2021 [2].
• Post-Biosimilar Era: Revenue is projected to experience a substantial decrease starting from 2026-2027.
  • 2026: Potential decline of 5-10% as initial biosimilar preparations and early launches occur.
  • 2027-2028: Significant revenue drop of 15-25% annually as biosimilars gain traction.
  • 2029 onwards: Revenue stabilization at a lower level, with continued gradual declines as the market matures and competition intensifies.

Impact on Treatment Access

Biosimilar availability is anticipated to improve access to golimumab therapy. The reduced cost of biosimilars can make these biologic treatments more affordable for a broader patient population, especially for healthcare systems and patients facing budget constraints. This could lead to an increase in the overall utilization of TNF-alpha inhibitors for approved indications.

Key Takeaways

• SIMPONI's core composition of matter patents are set to expire in 2026 and 2027, paving the way for biosimilar competition.
• The first biosimilar entries are expected between 2026 and 2027, with broader market penetration in subsequent years.
• Biosimilar entry is projected to cause price erosion for golimumab, potentially ranging from 20% to 50% or more within five years.
• SIMPONI's market share is expected to decline significantly, potentially by 30-50% within five years post-biosimilar launch.
• Annual revenues for SIMPONI are projected to decrease substantially from 2026 onwards, with significant annual drops anticipated in 2027-2028.
• The availability of biosimilars is expected to enhance patient access to golimumab therapy due to reduced costs.

Frequently Asked Questions

When do the primary patents for SIMPONI expire?

The primary patents covering the composition of matter for golimumab, U.S. Patent Nos. 7,816,094 and 7,129,336, expire in August 2026 and September 2027, respectively.

What is the anticipated timeline for the first SIMPONI biosimilar launch?

The first SIMPONI biosimilars are anticipated to enter the market around 2026-2027, following the expiration of key patents.

How much price reduction can be expected with SIMPONI biosimilars?

Based on trends for other TNF-alpha inhibitor biosimilars, price reductions for SIMPONI are projected to be between 20% and 50% or more within five years of biosimilar market entry.

Will SIMPONI continue to be prescribed after biosimilar launch?

Yes, SIMPONI is expected to retain some market share due to existing patient and physician familiarity. However, biosimilars will capture a significant portion of new prescriptions and may convert existing patients.

What is the historical revenue performance of SIMPONI?

Janssen reported global sales for SIMPONI and SIMPONI ARIA of approximately $2.6 billion in 2021, indicating a strong pre-biosimilar market position.

---

Citations

[1] U.S. Food & Drug Administration. (n.d.). DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/ (Specific drug labels accessed for dosage and indication information).

[2] Johnson & Johnson. (2022). Form 10-K Annual Report for the fiscal year ended December 31, 2021. Retrieved from https://www.sec.gov/ (Accessed via SEC EDGAR database).